Navigation Links
Scios Inc. targets drug giants in arthritis war

Scios Inc. , a small California biotechnology company, is racing giant rivals to bring a pill to market that would displace injectable anti-inflammatory drugs and set a new standard in arthritis treatment. Scios' ambitions are much larger than its market capitalization of a little more than $1 billion. That's because the first company to commercialize an oral version of today's dominant injectable drugs could gain the lion's share of a market. //

Scios' drug has shown promise in early trials. But the size of the potential market makes it a prize that many big pharmaceuticals companies also covet. So far, Scios' prospects look good. The company's pill appears to inhibit an enzyme, known as the p38 kinase, which provokes inflammation.

Scios' lead comes in part because an earlier trailblazer, Vertex Pharmaceuticals Inc. , was forced to drop back after its lead p38 kinase inhibitor showed toxicity in high doses in some animals. There are also many competitors. They include drug giant GlaxoSmithKline, which first isolated the p38 kinase in the early 1990s. Glaxo's drug is in early stage clinical trials for rheumatoid arthritis, asthma and irritable bowel syndrome. Other rivals include Merck and Co. Inc. , Roche Holding Ltd. , Johnson and Johnson, and Amgen Inc.

Scion Inc. has completed trials in healthy humans and is now planning to test the drug in patients with rheumatoid arthritis. Most rivals have yet to reach this stage.
'"/>




Page: 1

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Vedic vibration technology- the new cure for arthritis
3. Tai chi helps arthritis
4. Periodontitis a common problem in patients with arthritis
5. New device for discerning Osteoarthritis
6. Herbal extract aids in rheumatoid arthritis
7. Osteoarthritis and Estrogen are connected
8. Hyaluronan supplementation therapy for Knee Osteoarthritis
9. Green tea beneficial in preventing osteoarthritis
10. Leech Therapy for Osteoarthritis
11. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: